News for BTX Stock

BlackRock Technology and Private Equity Term Trust (BTX) Commences Tender Offer for up to 50% of outstanding common shares BlackRock Announces Shareholder Approval of Strategy Changes to the BlackRock Technology and Private Equity Term Trust (BTX) Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Brooklyn ImmunoTherapeutics Announces Board Changes Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq Brooklyn ImmunoTherapeutics Reports Inducement Grants Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021 Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021 Brooklyn Immuno Reports Inducement Grants Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 Brooklyn ImmunoTherapeutics Reports Inducement Grants Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics Brooklyn ImmunoTherapeutics Reports Inducement Grants Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc. Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc. Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime